Theralink (THER)

Government authorities in the United States and other countries extensively regulate, among other things, the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of biologic products. In the United States, the FDA subjects pharmaceutical and biologic products to rigorous review under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations.

Company profile

Ticker

THER

Exchange

OTC

Website

www.oncbiomune.com

CEO

Brian Barnett

Incorporated

Nevada

Location

Louisiana

Fiscal year end

Sep 30

Sector

Health Technology > Oil and Gas

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

Former names

OncBioMune Pharmaceuticals, Inc, PediatRx Inc., QUINT MEDIA INC., Striker Energy Corp

SEC CIK

0001362703

Corporate docs

Articles of Incorporation & Bylaws

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

OncBioMune, Inc. ...

IRS number

202590810

THER stock data

1M 1Y 5Y

Press releases

From Benzinga Pro

Theralink® Technologies to Host Fireside Chat with Dr. Mick Ruxin, President and Chief Executive Officer, on June 22nd at 11:00 a.m. ET

15 Jun 22

DENVER, June 15, 2022 /PRNewswire/ -- Theralink Technologies (OTC:THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for breast cancer, today

Theralink(R) Technologies to Participate in the LD Micro Invitational Conference on June 7-9

2 Jun 22

Denver, Colorado--(Newsfile Corp. - June 2, 2022) - Theralink Technologies (OTC:THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for breast cancer, today

Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry

19 Apr 22

Theralink currently supports preclinical and clinical studies across 11 biopharma clients, including multinational corporations Ongoing discussions with existing clients for development of Companion Diagnostics, a large

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

23 May 22

29 Jun 22

30 Sep 22

Financial summary

Financial statements Chart THER financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 21	Sep 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Theralink earnings reports.

Recent insider trades

THER insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jun 22	Danica Holley	Warrants Common Stock	Other	Acquire J	No	No	0.0048	2,100,840	10.08K	2,100,840
15 Jun 22	Danica Holley	8% Convertible Promissory Note Common Stock	Other	Acquire J	No	No	50000	-	50K	-

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q3 2019

THER institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: billed, billing, case, CFO, Chair, code, contractually, Danica, effectuating, entertainment, finalized, finalizing, FIRNA, GYN, head, higher, Holley, jurisdiction, liver, Matthew, Motion, neck, OBMP, output, pending, PLA, prostate, quotient, Schwartz, space, successor, supply, THER, uncompleted, unconditional, unexercisable, unissued

Removed: acquiree, acquirer, affiliated, allocated, Ashton, cell, closed, currency, detail, developer, discontinued, eliminated, enable, evident, foreign, functional, gastrointestinal, grow, gynecologic, inactive, intercompany, Jeffery, measurable, measuring, metric, Mexican, Mexico, noncash, operated, Peso, predictive, reliably, signaling, translated, treating, whichever, Yvonne

From filing 10-Q 2022 Q2

Financial reports

View all

Notice of late quarterly filing

17 May 22

10-Q

2022 Q1